Ultralife (ULBI) Cash & Equivalents (2010 - 2026)

Ultralife's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $8.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 1.96% year-over-year to $8.9 million; the TTM figure through Mar 2026 stood at $8.9 million (up 1.96% YoY), while the FY2025 annual figure was $9.3 million, up 36.34% from the prior year.
• Cash & Equivalents was $8.9 million for Q1 2026 at Ultralife, down from $9.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $10.9 million in Q2 2025 to a low of $5.1 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $7.8 million across 5 years, with a median of $8.3 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents slumped 68.14% in 2022, then jumped 84.14% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $5.7 million in 2022, then surged by 79.91% to $10.3 million in 2023, then tumbled by 33.31% to $6.9 million in 2024, then jumped by 36.34% to $9.3 million in 2025, then retreated by 4.87% to $8.9 million in 2026.
• The last three Cash & Equivalents figures came in at $8.9 million (Q1 2026), $9.3 million (Q4 2025), and $9.3 million (Q3 2025), per Business Quant data.